Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot
We investigated whether a single blood measurement using the minimally invasive technique of a finger prick to draw a blood sample of 5 µl (to yield a dried blood spot (DBS)) is suitable for the assessment of flurbiprofen (FLB) metabolic ratio (MR). Ten healthy volunteers who had been genotyped for...
Gespeichert in:
| Veröffentlicht in: | Clinical pharmacology and therapeutics 2012-03, Vol.91 (3), p.489-496 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 496 |
|---|---|
| container_issue | 3 |
| container_start_page | 489 |
| container_title | Clinical pharmacology and therapeutics |
| container_volume | 91 |
| creator | Daali, Y Samer, C Déglon, J Thomas, A Chabert, J Rebsamen, M Staub, C Dayer, P Desmeules, J |
| description | We investigated whether a single blood measurement using the minimally invasive technique of a finger prick to draw a blood sample of 5 µl (to yield a dried blood spot (DBS)) is suitable for the assessment of flurbiprofen (FLB) metabolic ratio (MR). Ten healthy volunteers who had been genotyped for CYP2C9 were recruited as subjects. They received FLB alone in session 1 and FLB with fluconazole in session 2. In session 3, the subjects were pretreated for 4 days with rifampicin and received FLB with the last dose of rifampicin on day 5. Plasma and DBS samples were obtained between 0 and 8 h after FLB administration, and urine was collected during the 8 h after administration. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. FLB's apparent clearance values decreased by 35% in plasma and DBS during session 2 and increased by 75% in plasma and by 30% in DBS during session 3. Good correlations were observed between MRs calculated from urine, plasma, and DBS samples.
Clinical Pharmacology & Therapeutics (2012); 91 3, 489–496. doi:10.1038/clpt.2011.247 |
| doi_str_mv | 10.1038/clpt.2011.247 |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1038_clpt_2011_247</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CPTCLPT2011247</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3727-21f0bbd9d5b0b8de20ef4b652bd3146451f4090db56e3525633023ea8a61dbea3</originalsourceid><addsrcrecordid>eNp9kLtOwzAUhi0EoqUwsiIvjCm-xLmMpVBAKmpF0zmyYwcZuXFkp0LdeASekSfBUQtsTL_O0adzfn0AXGI0xohmN5VpuzFBGI9JnB6BIWaURAmj7BgMEUJ5lBOaDMCZ929hjPMsOwUDQghNCUuGoFg4buDMbJ3QrbO1auCz6riwRlfwhXfawon3yvuNajq49rp5hRyuQhj19fG5tDqs75xWEt4aayVctbY7Byc1N15dHHIE1rP7YvoYzRcPT9PJPKrC9zQiuEZCyFwygUQmFUGqjkXCiJAUx0nMcB2jHEnBEkVZqEspIlTxjCdYCsXpCET7u5Wz3jtVl63TG-52JUZlb6fs7ZS9nTLYCfzVnm-3YqPkL_2jIwDXB4D7ipva8abS_o9jacZiSgKX77l3bdTu_6_ldFlM58uin_sS3wSif8o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Daali, Y ; Samer, C ; Déglon, J ; Thomas, A ; Chabert, J ; Rebsamen, M ; Staub, C ; Dayer, P ; Desmeules, J</creator><creatorcontrib>Daali, Y ; Samer, C ; Déglon, J ; Thomas, A ; Chabert, J ; Rebsamen, M ; Staub, C ; Dayer, P ; Desmeules, J</creatorcontrib><description>We investigated whether a single blood measurement using the minimally invasive technique of a finger prick to draw a blood sample of 5 µl (to yield a dried blood spot (DBS)) is suitable for the assessment of flurbiprofen (FLB) metabolic ratio (MR). Ten healthy volunteers who had been genotyped for CYP2C9 were recruited as subjects. They received FLB alone in session 1 and FLB with fluconazole in session 2. In session 3, the subjects were pretreated for 4 days with rifampicin and received FLB with the last dose of rifampicin on day 5. Plasma and DBS samples were obtained between 0 and 8 h after FLB administration, and urine was collected during the 8 h after administration. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. FLB's apparent clearance values decreased by 35% in plasma and DBS during session 2 and increased by 75% in plasma and by 30% in DBS during session 3. Good correlations were observed between MRs calculated from urine, plasma, and DBS samples.
Clinical Pharmacology & Therapeutics (2012); 91 3, 489–496. doi:10.1038/clpt.2011.247</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1038/clpt.2011.247</identifier><identifier>PMID: 22237256</identifier><identifier>CODEN: CLPTAT</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Administration, Oral ; Adult ; Area Under Curve ; Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors ; Aryl Hydrocarbon Hydroxylases - genetics ; Aryl Hydrocarbon Hydroxylases - metabolism ; Biological and medical sciences ; Cytochrome P-450 CYP2C9 ; Dried Blood Spot Testing - methods ; Fluconazole - administration & dosage ; Flurbiprofen - blood ; Flurbiprofen - pharmacokinetics ; Flurbiprofen - urine ; Genotype ; Humans ; Hydrolysis ; Male ; Medical sciences ; Pharmacology. Drug treatments ; Rifampin - administration & dosage ; Young Adult</subject><ispartof>Clinical pharmacology and therapeutics, 2012-03, Vol.91 (3), p.489-496</ispartof><rights>2012 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3727-21f0bbd9d5b0b8de20ef4b652bd3146451f4090db56e3525633023ea8a61dbea3</citedby><cites>FETCH-LOGICAL-c3727-21f0bbd9d5b0b8de20ef4b652bd3146451f4090db56e3525633023ea8a61dbea3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1038%2Fclpt.2011.247$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1038%2Fclpt.2011.247$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25785432$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22237256$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Daali, Y</creatorcontrib><creatorcontrib>Samer, C</creatorcontrib><creatorcontrib>Déglon, J</creatorcontrib><creatorcontrib>Thomas, A</creatorcontrib><creatorcontrib>Chabert, J</creatorcontrib><creatorcontrib>Rebsamen, M</creatorcontrib><creatorcontrib>Staub, C</creatorcontrib><creatorcontrib>Dayer, P</creatorcontrib><creatorcontrib>Desmeules, J</creatorcontrib><title>Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin Pharmacol Ther</addtitle><description>We investigated whether a single blood measurement using the minimally invasive technique of a finger prick to draw a blood sample of 5 µl (to yield a dried blood spot (DBS)) is suitable for the assessment of flurbiprofen (FLB) metabolic ratio (MR). Ten healthy volunteers who had been genotyped for CYP2C9 were recruited as subjects. They received FLB alone in session 1 and FLB with fluconazole in session 2. In session 3, the subjects were pretreated for 4 days with rifampicin and received FLB with the last dose of rifampicin on day 5. Plasma and DBS samples were obtained between 0 and 8 h after FLB administration, and urine was collected during the 8 h after administration. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. FLB's apparent clearance values decreased by 35% in plasma and DBS during session 2 and increased by 75% in plasma and by 30% in DBS during session 3. Good correlations were observed between MRs calculated from urine, plasma, and DBS samples.
Clinical Pharmacology & Therapeutics (2012); 91 3, 489–496. doi:10.1038/clpt.2011.247</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Area Under Curve</subject><subject>Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Aryl Hydrocarbon Hydroxylases - metabolism</subject><subject>Biological and medical sciences</subject><subject>Cytochrome P-450 CYP2C9</subject><subject>Dried Blood Spot Testing - methods</subject><subject>Fluconazole - administration & dosage</subject><subject>Flurbiprofen - blood</subject><subject>Flurbiprofen - pharmacokinetics</subject><subject>Flurbiprofen - urine</subject><subject>Genotype</subject><subject>Humans</subject><subject>Hydrolysis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Rifampin - administration & dosage</subject><subject>Young Adult</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOwzAUhi0EoqUwsiIvjCm-xLmMpVBAKmpF0zmyYwcZuXFkp0LdeASekSfBUQtsTL_O0adzfn0AXGI0xohmN5VpuzFBGI9JnB6BIWaURAmj7BgMEUJ5lBOaDMCZ929hjPMsOwUDQghNCUuGoFg4buDMbJ3QrbO1auCz6riwRlfwhXfawon3yvuNajq49rp5hRyuQhj19fG5tDqs75xWEt4aayVctbY7Byc1N15dHHIE1rP7YvoYzRcPT9PJPKrC9zQiuEZCyFwygUQmFUGqjkXCiJAUx0nMcB2jHEnBEkVZqEspIlTxjCdYCsXpCET7u5Wz3jtVl63TG-52JUZlb6fs7ZS9nTLYCfzVnm-3YqPkL_2jIwDXB4D7ipva8abS_o9jacZiSgKX77l3bdTu_6_ldFlM58uin_sS3wSif8o</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Daali, Y</creator><creator>Samer, C</creator><creator>Déglon, J</creator><creator>Thomas, A</creator><creator>Chabert, J</creator><creator>Rebsamen, M</creator><creator>Staub, C</creator><creator>Dayer, P</creator><creator>Desmeules, J</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201203</creationdate><title>Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot</title><author>Daali, Y ; Samer, C ; Déglon, J ; Thomas, A ; Chabert, J ; Rebsamen, M ; Staub, C ; Dayer, P ; Desmeules, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3727-21f0bbd9d5b0b8de20ef4b652bd3146451f4090db56e3525633023ea8a61dbea3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Area Under Curve</topic><topic>Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Aryl Hydrocarbon Hydroxylases - metabolism</topic><topic>Biological and medical sciences</topic><topic>Cytochrome P-450 CYP2C9</topic><topic>Dried Blood Spot Testing - methods</topic><topic>Fluconazole - administration & dosage</topic><topic>Flurbiprofen - blood</topic><topic>Flurbiprofen - pharmacokinetics</topic><topic>Flurbiprofen - urine</topic><topic>Genotype</topic><topic>Humans</topic><topic>Hydrolysis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Rifampin - administration & dosage</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Daali, Y</creatorcontrib><creatorcontrib>Samer, C</creatorcontrib><creatorcontrib>Déglon, J</creatorcontrib><creatorcontrib>Thomas, A</creatorcontrib><creatorcontrib>Chabert, J</creatorcontrib><creatorcontrib>Rebsamen, M</creatorcontrib><creatorcontrib>Staub, C</creatorcontrib><creatorcontrib>Dayer, P</creatorcontrib><creatorcontrib>Desmeules, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Daali, Y</au><au>Samer, C</au><au>Déglon, J</au><au>Thomas, A</au><au>Chabert, J</au><au>Rebsamen, M</au><au>Staub, C</au><au>Dayer, P</au><au>Desmeules, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin Pharmacol Ther</addtitle><date>2012-03</date><risdate>2012</risdate><volume>91</volume><issue>3</issue><spage>489</spage><epage>496</epage><pages>489-496</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><coden>CLPTAT</coden><abstract>We investigated whether a single blood measurement using the minimally invasive technique of a finger prick to draw a blood sample of 5 µl (to yield a dried blood spot (DBS)) is suitable for the assessment of flurbiprofen (FLB) metabolic ratio (MR). Ten healthy volunteers who had been genotyped for CYP2C9 were recruited as subjects. They received FLB alone in session 1 and FLB with fluconazole in session 2. In session 3, the subjects were pretreated for 4 days with rifampicin and received FLB with the last dose of rifampicin on day 5. Plasma and DBS samples were obtained between 0 and 8 h after FLB administration, and urine was collected during the 8 h after administration. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. FLB's apparent clearance values decreased by 35% in plasma and DBS during session 2 and increased by 75% in plasma and by 30% in DBS during session 3. Good correlations were observed between MRs calculated from urine, plasma, and DBS samples.
Clinical Pharmacology & Therapeutics (2012); 91 3, 489–496. doi:10.1038/clpt.2011.247</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>22237256</pmid><doi>10.1038/clpt.2011.247</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9236 |
| ispartof | Clinical pharmacology and therapeutics, 2012-03, Vol.91 (3), p.489-496 |
| issn | 0009-9236 1532-6535 |
| language | eng |
| recordid | cdi_crossref_primary_10_1038_clpt_2011_247 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Administration, Oral Adult Area Under Curve Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors Aryl Hydrocarbon Hydroxylases - genetics Aryl Hydrocarbon Hydroxylases - metabolism Biological and medical sciences Cytochrome P-450 CYP2C9 Dried Blood Spot Testing - methods Fluconazole - administration & dosage Flurbiprofen - blood Flurbiprofen - pharmacokinetics Flurbiprofen - urine Genotype Humans Hydrolysis Male Medical sciences Pharmacology. Drug treatments Rifampin - administration & dosage Young Adult |
| title | Oral Flurbiprofen Metabolic Ratio Assessment Using a Single‐Point Dried Blood Spot |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A34%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20Flurbiprofen%20Metabolic%20Ratio%20Assessment%20Using%20a%20Single%E2%80%90Point%20Dried%20Blood%20Spot&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Daali,%20Y&rft.date=2012-03&rft.volume=91&rft.issue=3&rft.spage=489&rft.epage=496&rft.pages=489-496&rft.issn=0009-9236&rft.eissn=1532-6535&rft.coden=CLPTAT&rft_id=info:doi/10.1038/clpt.2011.247&rft_dat=%3Cwiley_cross%3ECPTCLPT2011247%3C/wiley_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/22237256&rfr_iscdi=true |